NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note issued to investors on Monday,Benzinga reports. The firm currently has a $34.00 price target on the stock.

NRXP has been the subject of a number of other research reports. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. BTIG Research reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $34.50.

NRx Pharmaceuticals Stock Up 3.3%

NASDAQ NRXP opened at $2.84 on Monday. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $6.01. The business’s fifty day simple moving average is $2.82 and its 200-day simple moving average is $2.54. The firm has a market cap of $56.26 million, a PE ratio of -1.27 and a beta of 1.63.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67). Research analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of NRXP. Anson Funds Management LP boosted its holdings in NRx Pharmaceuticals by 535.1% during the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after acquiring an additional 993,401 shares during the period. Geode Capital Management LLC lifted its position in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares in the last quarter. Millennium Management LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter valued at approximately $61,000. Finally, Squarepoint Ops LLC acquired a new position in shares of NRx Pharmaceuticals in the fourth quarter valued at approximately $56,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.